Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.90 |
| ▸ | MEN1 | O00255 | 1/20 | 0.90 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.90 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.90 |
| ▸ | NR3C1 | P04150 | 18/20 | 0.49 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10311797 | 0.94 | KDM4E (0.87) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL29610995 | 0.93 | KDM4E (0.85) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL21340660 | 0.89 | KDM4E (0.82) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL4875 | 0.89 | KDM4E (0.82) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL17273905 | 0.89 | KDM4E (0.79) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL6820239 | 0.89 | KDM4E (0.81) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL10455984 | 0.89 | KDM4E (0.81) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| Cortivazol SCHEMBL4969166 | 0.85 | KDM4E (0.74) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL1816131 | 0.84 | KDM4E (0.71) | KDM4EMEN1KMT2ANPSR1NR3C1 | |
| SCHEMBL22946293 | 0.83 | KDM4E (0.71) | KDM4EMEN1KMT2ANPSR1NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178726-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-20120178726-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-20120178726-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2012-07-12 | — | — | US | disclosed |
| US-8163724-B2 | Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-8163724-B2 | Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-8163724-B2 | Glucocorticosteroids, processes for their preparation, pharmaceutical compositions containing them and their use in therapy | ASTRAZENECA AB (SE) | 2012-04-24 | — | — | US | disclosed |
| US-20090286835-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286835-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| US-20090286835-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178726-A1 | NOVEL COMPOUNDS | F12, C1R, CXCR4 | KDM4E 1428/4885MEN1 1198/4885KMT2A 2856/4885 |
| US-20090286835-A1 | NOVEL COMPOUNDS | F12, C1R, CXCR4 | KDM4E 1428/4885MEN1 1198/4885KMT2A 2856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.